Alembic Pharma Gets USFDA Approval For Drug That Treats Worm Infections
Albendazole tablets are indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium.
(Source: Unsplash)
Alembic Pharmaceuticals on Thursday said it has received approval from the US health regulator to market a generic drug used to treat infections caused by worms.
The company has received approval from the US Food & Drug Administration for its Abbreviated New Drug Application Albendazole Tablets USP (200 mg), the drug maker said in a statement.
The approved ANDA is therapeutically equivalent to Impax Laboratories, Inc.'s LAlbenza tablets, it added.
Albendazole tablets are indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium.
It is also indicated for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus.
Alembic Pharma shares on Thursday ended 3.03% higher at Rs 1,148.50 apiece on the BSE, compared to a 0.18% decline in the BSE Sensex.
